• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Arctic Bioscience AS: Arctic Bioscience - Exercise of right to convert debt and issuance of shares

Arctic Bioscience
Read the release

With reference to the stock exchange notice of 13th of January 2025 regarding new financing via a convertible loan. An investor, which participated in the investor consortium contributing to the convertible loan of total NOK 15 million, has exercised his right to convert the outstanding debt into shares. Debt that will be converted is NOK 270 365. The conversion amount includes accrued interest. The conversion price is set at NOK 2,7896 per share based on the received conversion notice.

The Board of Directors will issue the shares, pursuant to authorization granted by the Company's General Meeting on 26th May 2025. Following the capital increase, the Company's shares outstanding will be 26 956 257 shares.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.